15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
8
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.

European Molecular Biology Laboratory
2
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.

University of Science and Technology
7
Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening.

Sejong University
10
Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.

Indiana University School of Medicine
1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.

Korea Research Institute of Bioscience and Biotechnology
50
Using small molecules to target protein phosphatases.

Max Planck Institute of Molecular Physiology
1
Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent.

China Medical University
13
Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.

Sejong University
15
Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors.

Korea Research Institute of Chemical Technology
7
Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.

University of Pittsburgh
11
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.

Shanxi University
8
Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors.

University of Pittsburgh
191
COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS

Augustine Therapeutics
11
Polyproline mimetics of proline-derived module-15

Forschungsverbund Berlin
23
Pyrrolidine derivatives and their use as complement pathway modulators

Novartis